| Literature DB >> 27431619 |
Satoshi Kato1, Hideki Murakami2, Satoru Demura2, Yoshiyasu Fujimaki2, Katsuhito Yoshioka2, Noriaki Yokogawa2, Hiroyuki Tsuchiya2.
Abstract
Spinal metastases (SMs) from thyroid cancers significantly reduce the quality of life by causing pain and neurological deficits and increase mortality. Complete surgical resection of isolated thyroid SMs is a promising treatment option; however, the postoperative outcome is unknown. This study aimed to compare the postoperative courses of patients undergoing complete resection of thyroid SMs with those of patients undergoing incomplete resection, with a minimum 4-year follow-up. We performed a retrospective analysis of 32 patients who underwent tumor excision surgery for thyroid SMs at our medical center during a 28-year period. Twenty patients underwent complete excision, and 12 underwent incomplete excision. Survival was defined as the time from the first spinal surgery to death or last follow-up. Kaplan-Meier analysis with the long-rank test was used to compare the overall survival rates between the groups. For all patients, the overall 5- and 10-year survival rates were 71% and 31%, respectively. The median overall survival time was 6.4 years. The patients undergoing complete excision survived longer than those undergoing incomplete excision (5-year survival: 84% vs. 50%; 10-year survival: 52% vs. 8%; P < 0.01). Only one patient undergoing complete excision experienced local tumor recurrence in the operated spine, whereas all long-term survivors (>18 months after surgery) in the incomplete excision group experienced local tumor recurrence and a consequent deterioration in performance status. Complete surgical resection of thyroid SMs, if achievable, has the potential not only to maintain performance status, but also to prolong survival.Entities:
Keywords: Metastasectomy; spinal metastases; spondylectomy; surgical resection; survival; thyroid carcinoma
Mesh:
Year: 2016 PMID: 27431619 PMCID: PMC5055174 DOI: 10.1002/cam4.823
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Figure 1Representative case of total en bloc spondylectomy. (A) Sagittal computed tomography showing a tumor involving L3 and L4. (B) Intraoperative photograph of the resected specimen. (C) Radiograph of the specimen showing the tumor resected en bloc.
Patient characteristics of the two groups
| Characteristic | Complete excision | Incomplete excision |
|
|---|---|---|---|
| No. of patients | 20 | 12 | |
| Men/women, No. | 2/18 | 5/7 | |
| PTC/FTC/MTC, No. | 6/13/1 | 4/8/0 | |
| Age (years), mean ± SD | 59.4 ± 10.3 | 62.5 ± 7.9 | 0.37 |
| Tokuhashi score | 12.9 ± 1.7 | 12.1 ± 1.4 | 0.17 |
| Tomita score | 2.9 ± 1.1 | 2.8 ± 0.7 | 0.85 |
| Vital organ metastases, No. (%) | 6 (30%) | 3 (25%) | 0.55 |
| Multiple metastases, No. (%) | 12 (60%) | 8 (66%) | 1.00 |
| Multiple SMs, No. (%) | 1 (5%) | 3 (25%) | 0.14 |
| Synchronous SMs, No. (%) | 5 (25%) | 4 (33%) | 0.70 |
| Cervical or L5 lesion, No. (%) | 1 (5%) | 6 (50%) | 0.02 |
| Revision surgery ( | 1 (5%) | 3 (25%) | 0.14 |
| Radioiodine therapy, No. (%) | 13 (65%) | 7 (58%) | 0.50 |
| External radiotherapy, No. (%) | 5 (25%) | 4 (33%) | 0.45 |
| Bisphosphonate or denosumab administration, No. (%) | 9 (45%) | 5 (42%) | 0.85 |
PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; MTC, medullary thyroid carcinoma; SD, standard deviation; SM, spinal metastases; L5, the fifth lumbar vertebra.
In the 4 patients, we performed revision surgery for symptomatic tumor recurrence after surgery at another hospital.
Figure 2The overall survival of the 32 patients undergoing surgical resection of spinal metastases from thyroid cancer. The 5‐ and 10‐year cancer‐specific survival rates were 71% and 31%, respectively. The tick marks indicate the last dates of follow‐up.
Figure 3Comparison of the overall survival of the complete excision group with that of the incomplete excision groups. The patients in the complete excision group survived longer than those in the incomplete excision group (5‐year survival: 84% vs. 50%; 10‐year survival: 52% vs. 8%; P < 0.01). The tick marks indicate the last dates of follow‐up.
Univariate analysis to identify factors associated with survival
| Factor |
| 5 (& 10)‐year survival rate, % |
|
|---|---|---|---|
| Surgery of spinal metastaes | |||
| Complete resection | 20 (62.5) | 83.6, (52.2) | 0.006 |
| Incomplete resection | 12 (37.5) | 50.0, (8.3) | |
| Histology | |||
| Papillary | 10 (31.2) | 50.0, (18.8) | 0.047 |
| Nonpapillary | 22 (68.8) | 81.0, (35.5) | |
| Lung metastases at spine surgery | |||
| Yes | 9 (28.1) | 66.7, (17.8) | 0.171 |
| No | 23 (71.9) | 73.0, (37.1) | |
| Extent of metastases at spine surgery | |||
| Single in the spine | 12 (37.5) | 83.3, (47.6) | 0.070 |
| Multiple (spine or other sites) | 20 (62.5) | 64.2, (20.0) | |
| Extent of spinal metastases at spine surgery | |||
| Single | 28 (87.5) | 75.0, (37.2) | 0.104 |
| Multiple | 4 (12.5) | 50.0, (25.0) | |
| Type of spinal metastases | |||
| Synchronous | 9 (28.1) | 77.8, (16.7) | 0.380 |
| Metachronous | 23 (71.9) | 68.2, (38.4) | |
| Radioiodine therapy | |||
| Yes | 20 (62.5) | 75.0, (20.5) | 0.553 |
| No | 12 (37.5) | 64.3, (42.9) | |
| External radiotherapy | |||
| Yes | 9 (28.1) | 77.8, (46.7) | 0.797 |
| No | 23 (71.9) | 69.0, (25.9) | |
| Bisphosphonate or denosumab administration | |||
| Yes | 14 (43.7) | 63.5, (39.7) | 0.857 |
| No | 18 (56.3) | 77.8, (24.7) | |
Figure 4Comparison of the overall survival of patients with lung metastases with that of patients without lung metastases. No significant difference was observed between the two groups. The tick marks indicate the last dates of follow‐up.